Abstract
Objective: This study evaluates the hypoglycemic effects and glucose tolerance improvement of a dietary compound tablet containing cinnamon extract, chromium-rich yeast, mulberry leaf extract, zinc citrate, and selenium-rich yeast in alloxan-induced hyperglycemic mice.
Methods: Hyperglycemia was induced in SPF-grade Kunming mice through intravenous administration of alloxan at a dose of 45 mg/kg. Subsequently, the mice were randomly divided into a control group and treatment groups receiving low (66.67 mg/kg), medium (133.34 mg/kg), or high (400 mg/kg) doses of the compound tablet. Following 30 days of continuous oral gavage, fasting blood glucose levels, glucose tolerance, and the area under the glucose curve (AUC) were assessed. Statistical comparisons among groups were performed using one-way analysis of variance (ANOVA).
Results: Fasting blood glucose levels in the medium- and high-dose groups decreased significantly by 18.3% and 24.7%, with corresponding AUC reductions of 32.5% and 41.2% (p0.05). Body weight remained unchanged across all groups (p>0.05).
Novelty: This study uniquely evaluates a novel dietary compound tablet containing cinnamon, chromium, mulberry leaf, zinc, and selenium for hyperglycemia management. Unlike previous research focusing on individual components, this work demonstrates the significant, dose-dependent glucose-lowering effects and improved glucose tolerance of this specific combination in alloxan-induced hyperglycemic mice. This finding highlights the enhanced potential of this multi-ingredient formulation as an adjuvant treatment for diabetes, warranting further clinical investigation.
Conclusion: In hyperglycemic mice, administration of the dietary compound tablet resulted in significant, dose-dependent reductions in blood glucose levels and enhanced glucose tolerance. These results highlight its potential utility as an adjunctive therapy for diabetes. However, further clinical investigations are necessary to validate its efficacy and safety.
Keywords: Dietary compound tablet, alloxan, hyperglycemic model, glucose tolerance, bioactive compounds.